Psoriasis - Cudurka Psoriasis https://en.wikipedia.org/wiki/Psoriasis
Cudurka Psoriasis waa cudur difaaca jirka oo muddo dheer jira, aan la kala qaadin oo lagu garto meelaha sare ee maqaarka aan caadiga ahayn. Meelahani waa casaan, ama guduudan dadka qaarkiis oo maqaarkoodu madow yahay, engegan, cuncun, iyo qolof leh. Dhaawaca maqaarku wuxuu kicin karaa isbeddellada maqaarka ee psoriatic goobtaas, taas oo loo yaqaan "Koebner phenomenon (phenomenon Koebner)".

Daawooyin kala duwan ayaa kaa caawin kara xakamaynta calaamadaha. Daawayntan waxaa ka mid ah kiriimyada isteeroodhka, kareemka fitamiin D3, iftiinka ultraviolet, iyo dawooyinka difaaca jirka, sida methotrexate. Qiyaastii 75% ka qayb qaadashada maqaarku waxay ku hagaagtaa kiriimyada oo keliya. Waxyaalaha difaaca jirka ee nafleyda oo kala duwan ayaa loo sameeyay daawaynta cudurka psoriasis.

Psoriasis waa cillad caadi ah oo cudurku wuxuu saameeyaa 2-4% dadweynaha. Ragga iyo dumarka ayaa saameeya soo noqnoqoshada siman. Cudurku wuxuu bilaabmi karaa da' kasta, laakiin caadi ahaan wuxuu ku bilaabmaa qaan-gaarnimada. Psoriatic arthritis-ku wuxuu saameeyaa ilaa 30% shakhsiyaadka qaba cudurka psoriasis .

Daawaynta - Daawooyinka OTC
Iftiinka qorraxdu wuxuu caawin karaa cudurka psoriasis sababtoo ah soo-gaadhista qorraxdu waxay keentaa isbeddello difaac oo bukaannada qaba cudurka psoriasis. Boomaatada hydrocortisone ee khafiifka ah ayaa laga yaabaa inay caawiso daawaynta nabarada yaryar ee psoriasis.
#OTC steroid ointment

Daawaynta
Psoriasis waa cudur dabadheeraad ah waxaana la daraaseeyaa wax badan oo daawooyin ah. Bayolojigu waa kuwa ugu waxtarka badan laakiin aad u qaali ah.
#High potency steroid ointment
#Calcipotriol cream
#Phototherapy
#Biologics (e.g. infliximab, adalimumab, secukinumab, ustekinumab)
Macluumaad dheeraad ah ― Somali
References Psoriasis 28846344 
NIH
 Phototherapy 33085287 
NIH
 Tumor Necrosis Factor Inhibitors 29494032 
NIH
Tumor necrosis factor (TNF)-alpha inhibitors, including etanercept (E), infliximab (I), adalimumab (A), certolizumab pegol (C), and golimumab (G), are biologic agents which are FDA-approved to treat ankylosing spondylitis (E, I, A, C, and G), Crohn disease (I, A and C), hidradenitis suppurativa (A), juvenile idiopathic arthritis (A), plaque psoriasis (E, I and A), polyarticular juvenile idiopathic arthritis (E), psoriatic arthritis (E, I, A, C, and G), rheumatoid arthritis (E, I, A, C, and G), ulcerative colitis (I, A and G), and uveitis (A).